Compare · BIIB vs XTNT
BIIB vs XTNT
Side-by-side comparison of Biogen Inc. (BIIB) and Xtant Medical Holdings Inc. (XTNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and XTNT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $34.40B, about 769.9x XTNT ($44.7M).
- BIIB has hit the wire 5 times in the past 4 weeks while XTNT has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 1 for XTNT).
- Company
- Biogen Inc.
- Xtant Medical Holdings Inc.
- Price
- -
- -
- Market cap
- $34.40B
- $44.7M
- 1M return
- +6.75%
- -
- 1Y return
- +64.37%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 1
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Xtant Medical Holdings Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Latest BIIB
- Biogen upgraded by Analyst with a new price target
- SEC Form 4 filed by Biogen Inc.
- Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
- Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
- Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
- Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
- A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- SEC Form 4 filed by Biogen Inc.
Latest XTNT
- Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market
- Director Lipschultz Tyler was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)
- Director Bakewell John K was granted 215,517 shares, increasing direct ownership by 24% to 1,129,633 units (SEC Form 4)
- Director Beeson Jonn R. was granted 215,517 shares, increasing direct ownership by 42% to 733,136 units (SEC Form 4)
- Director Jain Abhinav was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)
- Director Vizirgianakis Stavros G. was granted 323,275 shares, increasing direct ownership by 4% to 7,838,845 units (SEC Form 4)
- Chief Operating Officer Schallenberger Mark A. was granted 450,000 shares and covered exercise/tax liability with 7,070 shares, increasing direct ownership by 67% to 1,106,087 units (SEC Form 4) (withholding obligation)
- CFO and Assistant Secretary Neils Scott C was granted 400,000 shares and covered exercise/tax liability with 28,155 shares, increasing direct ownership by 44% to 1,215,226 units (SEC Form 4) (for withholding tax)
- President and CEO Browne Sean E was granted 550,000 shares and covered exercise/tax liability with 10,605 shares, increasing direct ownership by 21% to 3,114,669 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Xtant Medical Holdings Inc.